MNAT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL558222	0.53	15/20
SCHEMBL558223	0.53	15/20
SCHEMBL559356	0.51	14/20
SCHEMBL517413	0.54	13/20
SCHEMBL559412	0.54	13/20
SCHEMBL559413	0.54	13/20
SCHEMBL84411	0.50	11/20
SCHEMBL889079	0.49	11/20
SCHEMBL558878	0.51	10/20
SCHEMBL517461	0.53	9/20
SCHEMBL268925	0.46	9/20
SCHEMBL269583	0.46	9/20
SCHEMBL517664	0.48	8/20
SCHEMBL559189	0.47	8/20
SCHEMBL558710	0.45	8/20
SCHEMBL558711	0.45	8/20
SCHEMBL559506	0.45	8/20
SCHEMBL559507	0.45	8/20
SCHEMBL559349	0.44	8/20
SCHEMBL559996	0.44	8/20

Clinical trials — most relevant to MNAT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.	nan	UNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Markers and Mechanisms of Macrovascular Disease in IDDM	nan	COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MNAT1 binder may also engage these)

Protein	Name	Similarity
P51949	—	1.000	P51949 →
P51951	—	0.997	P51951 →
E1C760	—	0.986	E1C760 →
Q9D479	—	0.985	Q9D479 →
Q96G28	—	0.984	Q96G28 →
D3ZND0	—	0.984	D3ZND0 →
CDC37	Hsp90 co-chaperone Cdc37	0.983	landscape →
Q28E45	—	0.983	Q28E45 →
Q6PII3	—	0.983	Q6PII3 →
Q86UW7	—	0.983	Q86UW7 →
Q9JJT9	—	0.983	Q9JJT9 →
Q69ZX6	—	0.982	Q69ZX6 →
O08837	—	0.982	O08837 →
Q2KJC1	—	0.982	Q2KJC1 →
Q2IA00	—	0.982	Q2IA00 →
Q91WR3	—	0.982	Q91WR3 →
F7AEX0	—	0.982	F7AEX0 →
Q3ZC62	—	0.982	Q3ZC62 →
Q5PPY2	—	0.982	Q5PPY2 →
Q62717	—	0.982	Q62717 →
Q02225	—	0.982	Q02225 →
Q5PQS7	—	0.981	Q5PQS7 →
Q8R310	—	0.981	Q8R310 →
Q8C6E0	—	0.981	Q8C6E0 →
Q80TJ1	—	0.981	Q80TJ1 →
A5D796	—	0.981	A5D796 →
Q9H9C1	—	0.981	Q9H9C1 →
Q8BYR5	—	0.981	Q8BYR5 →
Q5EAW4	—	0.981	Q5EAW4 →
Q69ZZ6	—	0.981	Q69ZZ6 →